Currently approved weight management pharmacotherapy in the UK includes: Semaglutide (Wegovy) a GLP-1 receptor agonist approved by the MHRA for chronic weight management in adults, subject to NICE Technology Appraisal eligibility criteria [3] [5] Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist approved by the MHRA for the treatment of type 2 diabetes
GLP-1 drugs, which include medications used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have greatly increased in popularity in recent years due to their demonstrated effectiveness
Tirzepatide is also a once-weekly injectable, but it works on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Back Schuler, J, Shearin, E (2005) 'Amylin and Lilly announce FDA approval of BYETTA(TM) (Exenatide) Injection', Lilly News Release
The effects of aerobic exercise training on serum osteocalcin, adipocytokines and insulin resistance on obese young males
However, there may be a link to gallbladder-related events
